Product Description
Inhibition of cathepsin S by a specific inhibitor, RO5459072, in human PBMCex vivoresulted in accumulation of Lip10 in B cells and myeloid dendritic cells, but not in plasmacytoid dendritic cells and only to a minor degree in monocytes.
Mechanisms of Action: CTSS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Psoriasis|Sjogren's Syndrome
Phase 1: Healthy Volunteers|Drug Hypersensitivity|Hypersensitivity, Delayed|Celiac Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2018-002446-36 | P2 |
Completed |
Psoriasis |
2019-09-05 |
|
| 2015-004476-30 | P2 |
Completed |
Unknown |
2017-10-10 |
|
| BP30037 | P2 |
Completed |
Sjogren's Syndrome |
2017-07-10 |
|
| BP29911 | P1 |
Completed |
Celiac Disease |
2016-08-28 |